29.04.19: Not intended for U.S. and UK Media

Study reaffirms safety and efficacy profile of Xarelto™ for the prevention of stroke in patients with atrial fibrillationFirst results from RELOADED, an observational study in the EU, indicate that non-vitamin-K oral anticoagulants (NOACs) like Xarelto provide a benefit in renal preservation over time when compared to the vitamin-K antagonist (VKA) phenprocoumon / The data from the comparative effectiveness study in Germany confirm an improved safety outcome and comparable effectiveness for Xarelto compared with phenprocoumon in patients with non-valvular atrial fibrillation (NVAF), including those with renal insufficiency(1)mehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news